What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Surgery
Joachim Sieper mainly investigates Ankylosing spondylitis, Internal medicine, Spondylitis, Surgery and Physical therapy.
His specific area of interest is Ankylosing spondylitis, where he studies Sacroiliitis.
Joachim Sieper regularly links together related areas like Placebo in his Internal medicine studies.
Joachim Sieper has researched Spondylitis in several fields, including Back pain, Prospective cohort study, Axial spondyloarthritis and Epidemiology.
Joachim Sieper interconnects Gastroenterology, Cohort and Enthesitis in the investigation of issues within Surgery.
His Physical therapy research incorporates themes from Psoriatic arthritis, Psychological distress, Elderly population and Low back pain.
His most cited work include:
- The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis (837 citations)
- Prevalence of spondylarthropathies in HLA‐B27 positive and negative blood donors (769 citations)
- What low back pain is and why we need to pay attention (761 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Ankylosing spondylitis, Internal medicine, Axial spondyloarthritis, Surgery and Physical therapy.
His studies deal with areas such as Etanercept, Rheumatoid arthritis and Pathology as well as Ankylosing spondylitis.
His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology and Placebo.
His Axial spondyloarthritis study combines topics in areas such as Spondylarthritis, Radiology, Radiography and Cohort.
The concepts of his Surgery study are interwoven with issues in Infliximab, Clinical trial, Severity of illness and Enthesitis.
His biological study spans a wide range of topics, including Back pain and Epidemiology.
He most often published in these fields:
- Ankylosing spondylitis (59.95%)
- Internal medicine (46.86%)
- Axial spondyloarthritis (26.96%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (46.86%)
- Ankylosing spondylitis (59.95%)
- Axial spondyloarthritis (26.96%)
In recent papers he was focusing on the following fields of study:
Joachim Sieper mostly deals with Internal medicine, Ankylosing spondylitis, Axial spondyloarthritis, In patient and Radiography.
In Internal medicine, Joachim Sieper works on issues like Placebo, which are connected to Adverse effect, Randomized controlled trial, Clinical endpoint and Tolerability.
Ankylosing spondylitis is a subfield of Surgery that Joachim Sieper studies.
His Axial spondyloarthritis research is multidisciplinary, incorporating elements of Magnetic resonance imaging, Radiology, Sacroiliac joint, Back pain and Cohort.
Joachim Sieper focuses mostly in the field of Radiography, narrowing it down to topics relating to Sacroiliitis and, in certain cases, INCEPTION COHORT.
His Spondylitis study integrates concerns from other disciplines, such as Etanercept and Cohort study.
Between 2016 and 2021, his most popular works were:
- What low back pain is and why we need to pay attention (761 citations)
- Prevention and treatment of low back pain: evidence, challenges, and promising directions. (529 citations)
- Low back pain: a call for action (308 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Surgery
His primary areas of investigation include Ankylosing spondylitis, Internal medicine, Placebo, Axial spondyloarthritis and Clinical trial.
Joachim Sieper studies Sacroiliitis which is a part of Ankylosing spondylitis.
His study in the fields of Spondylitis, Rheumatology and Disease under the domain of Internal medicine overlaps with other disciplines such as In patient.
His Placebo research is multidisciplinary, relying on both Adverse effect, Clinical endpoint, Randomized controlled trial and Adalimumab.
The various areas that Joachim Sieper examines in his Axial spondyloarthritis study include Back pain, Physical therapy and Treatment targets.
As part of the same scientific family, Joachim Sieper usually focuses on Clinical trial, concentrating on Ixekizumab and intersecting with Injection site reaction.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
